Trial odds, evidence history, and stock impact in one biotech analytics surface.
RxStrata tracks upcoming catalysts, reconstructs what prior trial history actually says, estimates pass odds from evidence quality, and frames the listed stock reaction before the market gets the result.
Upcoming clinical and regulatory catalysts with hard versus estimated timing kept separate.
Trial-by-trial briefs on prior history, current pass odds, and the likely stock-reaction envelope.
Append-only catalyst ledger with direct links back to registry, SEC, FDA, EMA, and company sources.
Deterministic odds and impact math first, then a short model rewrite for narrative polish only.
Upcoming catalysts
—
Scheduled trial and regulatory rows currently surfaced by the ledger.
Average pass odds
—
Late-stage setup confidence from the rule engine before narrative rewrite.
Hard-date radar
0
Watchlist entries carrying an official or otherwise fixed catalyst date.
The next setups worth triaging
Each card is meant to answer the practical trading questions fast: what is the catalyst, what does the prior record look like, what are the current odds, and which stock actually moves if the readout lands.
Current UX findings
The scaffold had too much dead space above the fold, watchlist rows were not framed as tradeable setups, and the evidence drawer still contained a fake chart. This build tightens the information hierarchy and removes placeholder market visuals.